L. Historique-du, C. , and .. , 64 3.1.2. Propriétés du lipiodol, ., p.68

C. Travaux-sur-l-'optimisation-du-vecteur-pour-la and C. , 112 2.1. Optimisation d'une CHE lipiodolée : essai randomisé de phase II comparant une CHE à base de lipiodol et d'anthracycline avec ou sans amiodarone chez des patients atteints d'un CHC non résécable, p.112

L. Adams, J. Lymp, S. Sauver, and J. , The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study, Gastroenterology, vol.129, issue.1, pp.113-121, 2005.
DOI : 10.1053/j.gastro.2005.04.014

J. Aguilar, S. Hussein, and P. Cerutti, Aflatoxin B1 induces the transversion of G-->T in codon 249 of the p53 tumor suppressor gene in human hepatocytes., Proc. Natl. Acad. Sci. USA, pp.8586-8590, 1993.
DOI : 10.1073/pnas.90.18.8586

L. France, épidémiologie, étiologie, traitement et survie. XXIVème forum de cancérologie, Bull Cancer, vol.91, p.503, 2004.

*. Boulin, M. Guiu, B. Guiu, S. Cercueil, J. Bedenne et al., Etude de cytotoxicité in vitro des différents anticancéreux candidats à la chimioembolisation des carcinomes hépatocellulaires Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference, Gastroenterol Clin Biol J Hepatol, vol.33, issue.35, pp.421-430, 2001.

*. Chauffert, B. Martin, M. Hammann, A. Michel, M. Martin et al., Amiodarone-induced enhancement of doxorubicin and 4'-deoxydoxorubicin cytotoxicity to rat colon cancer cells in vitro and in vivo, Cancer Res, vol.46, pp.825-830, 1986.

*. Chauffert, B. Rey, D. Coudert, B. Dumas, M. Martin et al., Amiodarone is more efficient than verapamil in reversing resistance to anthracyclines in tumour cells, British Journal of Cancer, vol.56, issue.2, pp.119-122, 1987.
DOI : 10.1038/bjc.1987.167

M. Colombo, Hepatocellular Carcinoma in Cirrhotics, Seminars in Liver Disease, vol.9, issue.04, pp.374-383, 1993.
DOI : 10.1055/s-2007-1007366

*. Doffoel, M. Bonnetain, F. Bouché, and O. , Multicentre randomised phase III trial comparing Tamoxifen alone or with Transarterial Lipiodol Chemoembolisation for unresectable hepatocellular carcinoma in cirrhotic patients (F??d??ration Francophone de Canc??rologie Digestive 9402), European Journal of Cancer, vol.44, issue.4, pp.528-538, 2008.
DOI : 10.1016/j.ejca.2008.01.004

*. Ebied, O. Federle, M. Carr, and B. , Evaluation of responses to chemoembolization in patients with unresectable hepatocellular carcinoma, Cancer, vol.16, issue.4, pp.1042-50, 2003.
DOI : 10.1002/cncr.11111

*. El-serag, H. Rudolph, and K. , Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis, Gastroenterology, vol.132, issue.7, pp.2257-2276, 2007.
DOI : 10.1053/j.gastro.2007.04.061

*. Farges, O. Regimbeau, J. Belghiti, and J. , Aggressive management of recurrence following surgical resection of hepatocellular carcinoma, Hepatogastroenterology, vol.45, pp.1275-1280, 1998.

*. Favoulet, P. Cercueil, J. Faure, and P. , Increased cytotoxicity and stability of Lipiodol-pirarubicin emulsion compared to classical doxorubicin-Lipiodol: potential advantage for chemoembolization of unresectable hepatocellular carcinoma, Anti-Cancer Drugs, vol.12, issue.10, pp.801-806, 2001.
DOI : 10.1097/00001813-200111000-00003

*. Grosso, M. Vignali, C. Quaretti, and P. , Transarterial Chemoembolization for Hepatocellular Carcinoma with Drug-Eluting Microspheres: Preliminary Results from an Italian Multicentre Study, CardioVascular and Interventional Radiology, vol.16, issue.6, pp.1141-1149, 2008.
DOI : 10.1007/s00270-008-9409-2

. Chimiothérapie-couplée-au-lipiodol®, Etude in vitro de la cinétique de libération de l'adriamycine, Gastroenterol Clin Biol, vol.13, pp.775-778, 1989.

*. Hong, K. Khwaja, A. Liapi, E. Torbenson, M. Georgiades et al., New Intra-arterial Drug Delivery System for the Treatment of Liver Cancer: Preclinical Assessment in a Rabbit Model of Liver Cancer, Clinical Cancer Research, vol.12, issue.8, pp.2563-2567, 2006.
DOI : 10.1158/1078-0432.CCR-05-2225

*. Johnson, P. Kalayci, C. Dobbs, and N. , Pharmacokinetics and toxicity of intra-arterial of adriamycin for hepatocellular carcinoma:effects of coadministration of lipiodol, J Hepatol, vol.11, pp.349-353, 1990.

C. Kalayci, P. Johnson, N. Roby, E. Metivier, and R. Williams, Intra-arterial doxorubicin and Lipiodol for inoperable hepatocellular carcinoma: a comparison with intravenous doxorubicin, J Hepatol, vol.13, pp.120-127, 1991.

*. Khan, K. Nakata, K. Kusumoto, and Y. , Evaluation of nontumorous tissue damage by transcatheter arterial embolization for hepatocellular carcinoma, Cancer Res, vol.51, pp.5667-5671, 1991.

J. Lammer, . Precision, and . Presentation, Prospective randomised study of doxorubicin in the treatment of hepatocellular carcinoma by Drug-Eluting Bead Embolisation, CIRSE, 2008.

*. Lee, H. Kim, K. Yoon, and J. , Therapeutic Efficacy of Transcatheter Arterial Chemoembolization as Compared With Hepatic Resection in Hepatocellular Carcinoma Patients With Compensated Liver Function in a Hepatitis B Virus???Endemic Area: A Prospective Cohort Study, Journal of Clinical Oncology, vol.20, issue.22, pp.4459-4465, 2002.
DOI : 10.1200/JCO.2002.02.013

R. Lencioni, A. Paolicchi, and M. Moretti, Combined transcatheter arterial chemoembolization and percutaneous ethanol injection for the treatment of large hepatocellular carcinoma: local therapeutic effect and long-term survival rate, European Radiology, vol.8, issue.3, pp.439-444, 1998.
DOI : 10.1007/s003300050409

*. Lewis, A. Gonzalez, V. Lloyd, and A. , DC Bead: In Vitro Characterization of a Drug-delivery Device for Transarterial Chemoembolization, Journal of Vascular and Interventional Radiology, vol.17, issue.2, pp.335-342, 2006.
DOI : 10.1097/01.RVI.0000195323.46152.B3

L. Li, P. Wu, and J. Li, Segmental transcatheter arterial embolization for primary hepatocellular carcinoma, World Journal of Gastroenterology, vol.4, issue.6, pp.511-512, 1998.
DOI : 10.3748/wjg.v4.i6.511

*. Llovet, J. Real, M. Montana, and X. , Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial, The Lancet, vol.359, issue.9319, pp.1734-1739, 2002.
DOI : 10.1016/S0140-6736(02)08649-X

*. Llovet, J. Burroughs, A. Bruix, and J. , Hepatocellular carcinoma, The Lancet, vol.362, issue.9399, pp.1907-1917, 2003.
DOI : 10.1016/S0140-6736(03)14964-1

*. Lo, C. Ngan, H. Tso, and W. , Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma, Hepatology, vol.12, issue.5, pp.1164-1171, 2002.
DOI : 10.1053/jhep.2002.33156

*. Malagri, K. Chatzimichael, K. Alexopoulou, and E. , Transarterial Chemoembolization of Unresectable Hepatocellular Carcinoma with Drug Eluting Beads: Results of an Open-Label Study of 62 Patients, CardioVascular and Interventional Radiology, vol.17, issue.11, pp.269-280, 2008.
DOI : 10.1007/s00270-007-9226-z

L. Marelli, R. Stigliano, and C. Triantos, Transarterial Therapy for Hepatocellular Carcinoma: Which Technique Is More Effective? A Systematic Review of Cohort and Randomized Studies, CardioVascular and Interventional Radiology, vol.76, issue.11, pp.6-25, 2007.
DOI : 10.1007/s00270-006-0062-3

O. Matsui, M. Kadoya, and T. Kameyam, Benign and malignant nodules in cirrhotic livers: distinction based on blood supply., Radiology, vol.178, issue.2, pp.493-497, 1991.
DOI : 10.1148/radiology.178.2.1846240

*. Mazziotti, A. Grazi, G. Cavallari, and A. , Surgical treatment of hepatocellular carcinoma on cirrhosis: a Western experience, Hepatogastroenterology, vol.45, pp.1281-1287, 1998.

*. Merten, G. Burgess, W. Gray, L. Holleman, J. Roush et al., Prevention of Contrast-Induced Nephropathy With Sodium Bicarbonate, JAMA, vol.291, issue.19, pp.2328-2334, 2004.
DOI : 10.1001/jama.291.19.2328

*. Minemura, M. Tanimura, H. Tabor, and E. , Overexpression of multidrug resistance genes MDR1 and cMOAT in human hepatocellular carcinoma and hepatoblastoma cell lines., International Journal of Oncology, vol.15, 1999.
DOI : 10.3892/ijo.15.3.559

O. Quigley, J. Shen, and L. , Continual Reassessment Method: A Likelihood Approach, Biometrics, vol.52, issue.2, pp.673-684, 1996.
DOI : 10.2307/2532905

*. O-'quigley, J. Pepe, M. Fisher, and L. , Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer, Biometrics, vol.46, issue.1, pp.33-48, 1990.
DOI : 10.2307/2531628

*. Remontet, L. Esteve, J. Bouvier, and A. , Cancer incidence and mortality in France over the period 1978-2000, Rev Epidemiol Sante Publique, vol.51, pp.3-30, 2003.
URL : https://hal.archives-ouvertes.fr/hal-00427472

*. Roovers, D. , V. Vliet, M. Bloem, A. Lokhorst et al., Idarubicin overcomes P-glycoprotein-related multidrug resistance: comparison with doxorubicin and daunorubicin in human multiple myeloma cell lines, Leukemia Research, vol.23, issue.6, pp.539-548, 1999.
DOI : 10.1016/S0145-2126(99)00041-7

*. Saffroy, R. Pham, P. Lemoine, A. Debuire, and B. , Biologie moléculaire et carcinoma hépatocellulaire : données actuelles et développements futures, Ann Biol Clin, vol.62, pp.649-656, 2004.

Y. Sasaki, S. Imaoka, and H. Kasugai, A new approach to chemoembolization therapy for hepatoma using ethiodized oil, cisplatin, and gelatin sponge, Cancer, vol.142, issue.6, pp.1194-1203, 1987.
DOI : 10.1002/1097-0142(19870915)60:6<1194::AID-CNCR2820600607>3.0.CO;2-T

M. Suzuki, H. Suzuki, and T. Yamamoto, Indication of chemoembolization therapy without gelatin sponge for hepatocellular carcinoma, Semin Oncol, vol.24, pp.110-115, 1997.

*. Tanaka, K. Nakamura, S. Numata, and K. , The long term efficacy of combined transcatheter arterial embolization and percutaneous ethanol injection in the treatment of patients with large hepatocellular carcinoma and cirrhosis, Cancer, vol.188, issue.1, pp.78-85, 1998.
DOI : 10.1002/(SICI)1097-0142(19980101)82:1<78::AID-CNCR9>3.0.CO;2-G

*. Tanz and Z. , Treatment of hepatocellular carcinoma and effectiveness in vitro and in vivo, Digestion Drugs Exp Clin Res, vol.59, issue.12, pp.556-562, 1986.

*. Tepel, M. Van-der-giet, M. Schwarzfeld, and C. , Prevention of Radiographic-Contrast-Agent???Induced Reductions in Renal Function by Acetylcysteine, New England Journal of Medicine, vol.343, issue.3, pp.180-184, 2000.
DOI : 10.1056/NEJM200007203430304

P. Therasse, S. Arbuck, and E. Eisenhauer, New Guidelines to Evaluate the Response to Treatment in Solid Tumors, JNCI: Journal of the National Cancer Institute, vol.92, issue.3, pp.205-216, 2000.
DOI : 10.1093/jnci/92.3.205

*. Trinchet, J. Ganne-carrie, N. Beaugrand, and M. , Intra-arterial chemoembolization in patients with hepatocellular carcinoma, Hepatogastroenterology, vol.45, pp.1242-1247, 1998.

*. Tumolo, S. Toffoli, G. Baerz, and A. , Oral idarubicin for the treatment of hepatocellular carcinoma Chemoembolization of hepatocellular carcinoma with drug eluting beads : efficacy and doxorubicin pharmacokinetics, Proc Am Soci Clin Oncol J Hepatol, vol.21, issue.46, pp.474-481, 2002.

*. Venook, A. Stagg, R. Lewis, and B. , Chemoembolization for hepatocellular carcinoma., Journal of Clinical Oncology, vol.8, issue.6, pp.1108-1114, 1990.
DOI : 10.1200/JCO.1990.8.6.1108

L. Visipaque, flacon verre 20 ml) 3400935202895 (1 flacon PP 50 ml) 3400935203328 (1 flacon PP 100 ml) 3400935203557 (1 flacon PP 150 ml) 3400935203908 (1 flacon PP 200 ml). 3400935202956 (10 flacons PP 50 ml). 3400935203496 (10 flacons PP 100 ml), AMM, vol.270, issue.34009338463361, p.3400935204097

. Prix, Visipaque 270 : 8.35 euros (1 flacon 20 ml). 19.97 euros (1 flacon 50 ml). 35.45 euros (1 flacon 100 ml). 65.65 euros (1 flacon 200 ml). 50, p.57

. Parmi, diabète de type II, reflux gastro-esophagien, insuffisance hépatocellulaire sur hépatocarcinome, varices oesophagiennes Son traitement habituel comporte : -depuis au moins janvier 2009 : Metformine 1000 x3/j, Pravastatine 40mg/j, LOPRIL 25 (Captopril) 3/j, Furosémide 20mg/j, Zolpidem 10 mg/j, TARDYFERON 80 (Sulfate ferreux) 2/j, pp.75-77, 2010.

. Ses-traitements-au-long-cours-sont-les-suivants, Amlodipine 10 mg/j, Metformine 1000 x3/j (stoppé le 10 juin) Clopidogrel 75mg/j stoppé le 14 juin, Allopurinol 300 mg/j, Celiprolol 200 mg/j, Esoméprazole 20 mg/j, Furosémide 40mg/j, Lisinopril 20mg/j, Pravastatine 20mg/j, Carbamazépine LP400mg, Trimétazidine 35 mg/j, Insuline (NOVOMIX 30) 62 UI matin et soir stoppée le 14 juin

. La-troponine-Était, Le patient reçoit 4 comprimés de Clopidogrel + 250 mg d'Acétylsalicylate de lysine en intraveineuse Il est muté en Cardiologie pour réalisation d'une coronarographie Cette dernière retrouve une sténose ostiale de l'IVA à 70% et une sténose serrée du tronc circonflexe dominante. La circonflexe a été dilatée grâce à un stent nu, permettant un bon résultat. Un guide de pression de l'IVA a été fait, ne conduisant à aucune dilatation. L'évolution a été favorable

L. 'investigateur-juge-cet-Évènement-non-relié-À-zavedos® and . Visipaque®, Selon lui, la causalité est douteuse pour les microbilles, Une autre cause avancée est la cirrhose

?. Cas-particuliers and . Surdosage, Aucun cas de surdosage n'a été signalé au cours de la période couverte par ce rapport. ? Grossesse / allaitement Aucun cas d'exposition durant la grossesse ou l'allaitement n'a été

. Au-vu-de-la, toxicité présentée par le 1 er patient (DLT), il a été décidé que les autres patients seraient traités avec une dose d'idarubicine